Senior Manager - Value and Access at Eli Lilly and Company

Sydney, New South Wales, Australia

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, HealthcareIndustries

Requirements

Tertiary qualification in a suitable science or health care related discipline or statistics
Post-graduate qualifications in HTA, health economics, public policy, or economics (highly regarded)
Previous experience in managing reimbursement submissions within Australia/New Zealand (or similar) health care system and/or pharmaceutical industry (5 or more years)
Strong understanding of the reimbursement processes (e.g., PBAC/MSAC, PTAC, PBS listing)

Responsibilities

Develop PRA strategies and plans for pipeline and existing products within a business unit portfolio, with the goal of broad and diverse market access
Develop innovative access solutions, and make recommendations to local, regional and global lead teams on the optimal PRA strategy for the portfolio
Identify any gaps, risks and possible solutions for the execution of the proposed PRA strategies
Lead cross-functional teams in the development and delivery of the various access solutions
Identify access environment shaping needs, and work with the public affairs team on the joint delivery of the environment shaping activities
Lead cross-functional teams in the development and submission of reimbursement dossiers to PBAC/MSAC and PTAC, and in the consultation and post-decision phases of the reimbursement process
Act as a project manager for sourcing clinical and economic inputs required for submission dossiers
Develop cost-minimisation models and analyse cost-utility models
Write some or all sections of HTA submissions
In conjunction with the pricing and analytics lead, develop business cases for internal pricing approvals
Act as a PRA therapeutic area lead and manage the affiliate relationship with regional and global PRA/HEOR colleagues
Work with Key Account Managers to develop regional and local level market access materials
Maintain up-to-date knowledge of HTA processes and criteria, and the broader access environment
Contribute as a constructive member of Brand, Value Access and Public Affairs (VAPA) and Value and Access Teams
Lead cross-functional working groups when developing and executing PRA strategies for new products and indications
Coach/mentor Value and Access team members

Skills

Pricing Strategy

Reimbursement Strategy

Market Access

PBAC Dossiers

MSAC Dossiers

PTAC Dossiers

Project Management

Stakeholder Engagement

Cross-Functional Leadership

Economic Analysis

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free